Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
New drug combination shows particularly good results in patients with HPV-negative head and neck cancer
2.
Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam Method
3.
Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma
4.
New analysis helps discern benign from malignant thyroid growths
5.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
1.
Environmental Carcinogen Avoidance in Precision Prevention
2.
The Ins and Outs of Glossectomy: What You Need to Know
3.
How Cancer Cells Evade Immune Destruction and the Fight Back
4.
Understanding Phyllodes Tumor: Symptoms, Diagnosis, and Treatment Options
5.
Essential Strategies in Hematology for Healthcare Excellence
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
4.
Should We Use DARA Up Front As First-Line Therapy in MM?
5.
Efficient Management of First line ALK-rearranged NSCLC - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge